Hydrazine hydrate (1:1) → 6-Phenyl-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester
반응식
[C:1]([O:5][C:6]([N:8]1[CH2:13][C:12](=[CH:14]O)[C:11](=O)[CH2:10][CH:9]1[C:17]1[CH:22]=[CH:21][CH:20]=[CH:19][CH:18]=1)=[O:7])([CH3:4])([CH3:3])[CH3:2].O.[NH2:24][NH2:25]>CO>[C:1]([O:5][C:6]([N:8]1[CH:9]([C:17]2[CH:22]=[CH:21][CH:20]=[CH:19][CH:18]=2)[CH2:10][C:11]2[NH:24][N:25]=[CH:14][C:12]=2[CH2:13]1)=[O:7])([CH3:4])([CH3:3])[CH3:2]참가 물질
4
실험 절차
Compound 51 (310 mg, 1.02 mmol) from the previous step was dissolved in MeOH (3 ml). Hydrazine monohydrate (0.1 ml, 2.04 mmol) was added to the solution and then stirred at room temperature for 1 hour. Solvent was removed under reduced pressure to afford a yellow gel as the desired product. LCMS 300.2 (M+1)
후처리
- customSolvent was removed under reduced pressure
출처 및 근거
- ORD 기록
- ord-5cb7788b0c2a435e9b5881cb3ca4164c
- 출처 데이터셋
- uspto-grants-2010_06
- 특허 번호
- US07732609B2
반응 노트
불러오는 중…